BioMimics 3D® Vascular Stent System
The Challenge: Peripheral Arterial Disease
People are living longer and with an increase in the incidence of obesity, diabetes and other contributing factors, claudication may cause substantial tissue changes and, in some scenarios, can lead to amputation and even death. The peripheral stent market is forecast to grow to $2 billion by 2024 driven by technological advances, an ageing population and an increase in co-morbidities.
The Approach: Alternative Technologies
Because the superficial femoral artery is a long, relatively straight vessel, it is exposed to low wall shear stress under resting conditions, predisposing it to atherosclerotic disease and confounding the healing process after endovascular injury. Straight stents further straighten the vessel and disturb blood flow, creating areas of low wall shear stress.
Drug coated balloons and drug eluting stents utilising Paclitaxel in the femoropopliteal segment have shown encouraging clinical results but recent publications on the safety of Paclitaxel has put their use under the spotlight and regulatory bodies around the world are advocating caution in their use.
The Solution: The BioMimics 3D Vascular Stent System
Veryan has developed innovative technology to improve the performance of vascular stents by adopting the principle of biomimicry; developing structures that imitate those occurring naturally.
The BioMimics 3D Vascular Stent System is a peripheral self-expanding stent with a unique 3D helical geometry which imparts a gentle helical shape to the stented artery.1